Chimeric Therapeutics (ASX:CHM) has announced the treatment of the first patient in the second dose cohort in City of Hope’s phase 1 clinical trial evaluating the safety and tolerability of its chlorotoxin CAR T (CLTX CAR T) cell therapy.
The company said the treatment of the first patient in the second dose cohort marks the introduction of dual routes of administration of CLTX CAR T cells with both intracranial intratumoral (ICT) and intracranial intraventricular (ICV) dosing.
City of Hope’s phase 1 clinical trial is expected to enrol 18-36 patients with MMP2+ progressive or recurrent glioblastoma over a 24- month period.
“We are very encouraged by the continued progress of the trial, moving to this important next phase with dose escalation and dual routes of administration,” said Jennifer Chow, Chimeric Therapeutics chief operating officer. “This is another significant milestone in the development of this important therapy for patients with progressive or recurrent glioblastoma.”